QUOTE AND NEWS
Benzinga  Aug 12  Comment 
In a report published Wednesday, HC Wainwright analyst Andrew S Fein resumed coverage of TG Therapeutics Inc. (NASDAQ: TGTX) with a Buy rating and a price target of $22. TG Therapeutics' product pipeline offered "internal and external...
Benzinga  Jul 7  Comment 
Tredegar Corporation (NYSE: TG) announced that Tredegar Film Products will downsize its manufacturing facility in Lake Zurich, Illinois. The facility, which currently employs 134 people, is expected to downsize over the next two years as products...
Motley Fool  Jun 18  Comment 
TG Therapeutics is off to the races after updating phase 2 results for one of its leading compounds. Find out what the buzz is all about, and whether you should be buying into it.
Benzinga  Jun 11  Comment 
TG Therapeutics, Inc. (Nasdaq: TGTX), today announced that clinical data for TG-1101 (ublituximab), the Company's novel glycoengineered anti-CD20 monoclonal antibody, and TGR-1202, the Company's once-daily PI3K delta inhibitor, will be presented...
Benzinga  Jun 1  Comment 
TG Therapeutics, Inc. (Nasdaq: TGTX), today announced clinical results from its ongoing study with TG-1101 (ublituximab), the Company's novel glycoengineered anti-CD20 monoclonal antibody in combination with the Company's oral, once-daily, PI3K...
Automotive World  May 13  Comment 
Ribbon cutting ceremony held on May 12 TG Fluid Systems USA Corporation (TGFSUS), a North American subsidiary of Toyoda Gosei Co., Ltd. (Kiyosu, Japan) that produces plastic fuel tubes and other plastic automotive components, has a acquired a new...
Automotive World  May 12  Comment 
Toyoda Gosei (Shanghai) Co., Ltd. (short name Shanghai TG) moved to a new location in the Minhang District of Shanghai in January of this year. A dedication ceremony was held on May 11. The ceremony was attended by government officials, customers...
Benzinga  Apr 20  Comment 
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the first presentation of preclinical data demonstrating single agent and combination activity of two of TG Therapeutics' IRAK4...
Forbes  Mar 24  Comment 
Branko Krstevski’s portfolio outperformed the best mutual fund manager in the U.S. for the past 10 years. Today, his biggest position is TG Therapeutics (NASDAQ:TGTX) which was up 300% last year. Here’s why he thinks it could double again...





 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki